Cem Ozgonul
Gulhane Training and Research Hospital, Turkey
Posters & Accepted Abstracts: Insights in Ophthalmology
Purpose: To report the clinical features and the treatment outcomes of patients with peripapillary choroidal neovascular membrane (CNVM) secondary to idiopathic intracranial hypertension (IIH). Methods: Retrospective multicenter chart review of patients diagnosed with peripapillary CNVM in the course of the treatment and follow-up of IIH. Results: Thirteen eyes of 10 patients were included in the study with the mean age of 35 years. The mean time frame from the diagnosis of IIH to CNVM occurrence was 41 months. Mean followup period was 8 months after CNVM formation. All patients were treated with acetazolamide for IIH. Seven eyes were observed and six eyes were given anti-vascular endothelial growth factor (anti-VEGF) injections, including bevacizumab, ranibizumab and aflibercept. All CNVMs regressed with subretinal fibrosis and improved vision. Papilledema resolved in only one eye, while the other 12 eyes had persistent papilledema at the last follow up. Conclusions: Peripapillary CNVM is a rare complication of IIH. Often, CNVM is a self-limited secondary complication of IIH and involutes spontaneously by adequate treatment of IIH. In vision threatening and/or persistent cases, intravitreal anti-VEGF treatment is a safe and effective therapeutic option.